Pharmacoeconomic implications of preference toward reference- versus generic-brand antidepressants in primary care

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

Cambridge Univ Press

Access Rights

info:eu-repo/semantics/openAccess

Abstract

Background: The prevalence of depression is gradually increasing worldwide with an increasing utilization of antidepressants. Nevertheless, despite their lower costs, generic-brand antidepressants were reported to be less prescribed. We aimed to examine the costs of reference- versus generic-brand antidepressant prescriptions in primary care practice.Methods: This cross-sectional study included electronic prescriptions for adult patients that contained antidepressants (World Health Organization's Anatomical Therapeutic Chemical (ATC) code: N06A), which were generated by a systematically selected sample of primary care doctors (n = 1431) in Istanbul in 2016. We examined the drug groups preferred, the reference- versus generic-brand status, and pharmacotherapy costs.Findings: The majority of the prescriptions were prescribed for women (71.8%), and the average age of the patients was 53.6 +/- 16.2 years. In prescriptions with a depression-related indication (n = 40 497), the mean number and cost of drugs were 1.5 +/- 1.0 and 22.7 +/- 26.4 United States Dollar ($) per prescription, respectively. In these prescriptions, the mean number and cost of antidepressants per encounter were 1.1 +/- 0.2 and $17.0 +/- 13.2, respectively. Reference-brand antidepressants were preferred in 58.2% of depression-related prescriptions, where the mean cost per prescription was $18.3 +/- 12.4. The mean cost per prescription of the generics, which constituted 41.8% of the antidepressants in prescriptions, was $15.1 +/- 11.4. We found that if the generic version with the lowest cost was prescribed instead of the reference-brand, the mean cost per prescription would be $12.9 +/- 11.2.Conclusions: Our study highlighted the substantial pharmacoeconomic impact of generic-brand antidepressant prescribing, whose preference over reference-brands could reduce the cost of antidepressant medication treatment by 17.5% in primary care, which could be approximately doubled if the cheapest generic antidepressant had been prescribed.

Description

Keywords

antidepressive agents, drug utilization, generic drugs, pharmacoeconomics, primary health care

Journal or Series

Primary Health Care Research & Development

WoS Q Value

Scopus Q Value

Volume

25

Issue

Citation

Endorsement

Review

Supplemented By

Referenced By